SPOTLIGHT -
Dr. Ganjoo on the Treatment of Metastatic Uterine Leiomyosarcoma
Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with metastatic uterine leiomyosarcoma.
Read More
Dr. Ganjoo Discusses the Risks of Morcellation
Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the risks of morcellation.
Dr. Ganjoo on the Treatment of Early-Stage Uterine Leiomyosarcoma
Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with early-stage uterine leiomyosarcoma.
Dr. Ganjoo on Therapies for Patients With Uterine Leiomyosarcomas
Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses therapies for patients with uterine leiomyosarcomas.
Dr. Ganjoo on the Rarity of Uterine Sarcomas
Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the rarity and diagnosis of uterine sarcomas.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC